Nov 19, 2026
Alfa Cytology focuses on radionuclide labeling, compound analysis, and preclinical studies, covering multiple stages of radiopharmaceutical development.
New York, United States, November 19, 2026 /MarketersMEDIA/ -- Radiolabeling is an important technical link in the development of radiopharmaceuticals and can be used for compound tracking, diagnostic imaging, and related pharmacological studies. However, completing the labeling is only part of the research process. Researchers also need to investigate the properties, stability, and biological behavior of the labeled compounds according to the project objectives to provide a basis for subsequent experiments. Alfa Cytology provides radiolabeling and related research services, including compound preparation, analysis, and preclinical studies.
The preparation of radiolabeled compounds involves the selection of labeling sites, optimization of synthesis routes, purification, and analysis of products. Specific plans need to be determined in combination with the characteristics of the compounds and the research purpose, and further research could also involve stability, pharmacokinetics, and biodistribution. Therefore, the research process not only needs to consider how to prepare the labeled compounds, but also needs to determine the corresponding analysis and evaluation methods according to the intended use.
After the preparation of the compounds, analytical studies help to further understand their properties and performance during the experiment. Alfa Cytology provides pharmacokinetic and pharmacodynamic (PK/PD) studies, biodistribution and dosimetry studies, and stability and shelf-life studies of radiolabeled compounds. Analytical methods also include high-performance liquid chromatography (HPLC), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and gamma counting. Depending on the research objectives of different projects, these methods can be used to investigate the relevant characteristics of compounds and provide an experimental basis for subsequent pharmacological research and preclinical evaluation.
Radiolabeling protocols also need to be selected according to the intended research application. Alfa Cytology's services include radiolabeling for PET, SPECT, and other studies, as well as the labeling of small molecules, biomolecules, and related conjugates. These techniques can be used in molecular imaging, drug research, and studies related to targeted radiotherapy. The appropriate approach depends on the properties of the compounds and the objectives of the project.
In addition to radiolabeling services, Alfa Cytology also provides research and development services related to radionuclide-drug conjugates (RDCs). RDC research and development involves components such as radionuclides, chelators, linkers, and targeting molecules, and needs to be designed and evaluated in combination with different coupling types and research phases. The services listed on the official website include RDC design, payload development, linker design and synthesis, chelator screening and synthesis, coupling, characterization, and preclinical research, covering different types of radionuclide coupling schemes such as antibodies, peptides, small molecules, and siRNA.
Radiolabeling and RDC-related studies can be applied to diagnostic imaging, targeted radiotherapy, and drug discovery. The evaluation focus of different projects depends on the candidate compounds and their research objectives, and may involve aspects such as compound stability, biodistribution, pharmacokinetics, or dosimetry. Combining compound preparation with subsequent analysis and preclinical studies helps researchers structure experiments around specific R&D questions, rather than just completing the labeling as an endpoint.
About Alfa Cytology
Alfa Cytology focuses on cancer research and related R&D services, covering drug discovery, radiopharmaceutical research, and preclinical research. The company provides technical services across different stages of research and development, including radiolabeling, radionuclide-drug conjugate (RDC) development, and compound analysis, for research areas such as diagnostic imaging, targeted radiotherapy, and drug development.
Contact Info:
Name: Toya Davis
Email: Send Email
Organization: Alfa Cytology
Website: https://www.rdcthera.com
Release ID: 89210124
Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.
In an interview at the DealBook Summit, the co-founders Sam Altman and Greg Brockman discussed how to strike a balance between safety and risk.
A 2026 Cost of Dying Report found direct cremation was now chosen for around one in five funerals.
MSPs have heard both the pros and cons of the government's plan to launch its first ever bond to the market.
"It's a really tough time for a lot of people," a sustainable food organisation says.
At an all-hands meeting with employees, Colette Kress sought to put the indiscretions of Nvidia’s co-founder, Jensen Huang, behind them.
Are you driving less? Car pooling? Using a different vehicle? Tell us how the 2026 energy shock has affected you.
Alibaba, the Chinese internet giant behind the company at the center of the Nvidia spy saga, has used its A.I. computing technology to aid a lab with links to China’s military.
Leaders in artificial intelligence and governments discussed America’s shifting politics, the reverberations of Jensen Huang’s ouster at Nvidia and more on Wednesday.
The multi-billionaire also said he was "not Maga", distancing himself from the political movement linked to Trump.
The artificial intelligence giant will become by far the largest publicly traded “public benefit corporation,” a structure that mandates it balance safety and profit.
Speaking alongside the Nasdaq chief Adena Friedman and the Polymarket founder Shayne Coplan, Vlad Tenev said regular investors should have access to more opportunities.
Graphics: The numbers behind China-US bilateral trade
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.